BSE Live
Mar 24, 16:01Prev. Close
369.00
Open Price
375.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 24, 15:54Prev. Close
368.75
Open Price
376.65
Bid Price (Qty.)
395.15 (550)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of SMS Pharmaceuticals (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 2.88 | 7.95 | 32.37 | 32.67 | 13.10 | |
| Net CashFlow From Operating Activities | 25.25 | 20.91 | 5.21 | 8.40 | 5.94 | |
| Net Cash Used In Investing Activities | -58.22 | -65.95 | -101.63 | -22.42 | -6.21 | |
| Net Cash Used From Financing Activities | 17.85 | 42.05 | 24.76 | 104.08 | 0.99 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -15.13 | -3.00 | -71.67 | 90.05 | 0.72 | |
| Cash And Cash Equivalents Begin of Year | 20.37 | 23.37 | 95.04 | 4.99 | 4.26 | |
| Cash And Cash Equivalents End Of Year | 5.25 | 20.37 | 23.37 | 95.04 | 4.99 |
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
09.02.2026
05.01.2026
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
14.11.2025
SMS Pharma Consolidated September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
12.11.2025
SMS Pharma Standalone September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
24.03.2026
24.03.2026
23.03.2026
Alkem Laboratories gets DCGI nod for Semaglutide Injection; share price fall marginally
23.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth